LentiGlobin continues to deliver in latest sickle cell update as bluebird outlines path to accelerated approval, despite patient death

Still reeling from the FDA’s stunning refusal to file its CAR-T therapy ide-cel, bluebird is eager to win back some credibility with a new …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lenti­Glo­bin con­tin­ues to de­liv­er in lat­est sick­le cell up­date as blue­bird out­lines path to ac­cel­er­at­ed ap­proval, de­spite pa­tient death